Informe completo: Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Resumen: Lenvatinib and sorafenib for differentiated thyroid cancer
Objetivo: The remit of this research was to assess the clinical effectiveness and cost-effectiveness of lenvatinib and sorafenib within their European Union marketing authorisations for the treatment of patients with RR-DTC.
Autoría: NIHR Health Technology Assessment programme
Idioma: inglés
Fuente: INAHTA
Año de publicación: 2020